At Danaher, we’re committed to accelerating the power of science and technology to
improve human health.
Our impact spans from lab to life, speeding the translation of advanced science to real-world impact and improving the lives of millions of patients globally.
Guided by our culture of continuous improvement, we’re turning scientific potential into progress and helping providers deliver accurate answers sooner —because time saves lives, and speed with certainty matters.
At Danaher we unite diagnostics, life sciences, and biotech to deliver faster, smarter solutions—because lives depend on it.
The impact of our industry-leading businesses - Beckman Coulter Diagnostics, Beckman Coulter Life Sciences, Cepheid, Cytiva, HemoCue, Leica Biosystems, Radiometer and SCIEX – spans from lab to life, speeding the translation of advanced science to real-world impact by:
|
Date: Tuesday July 28 |
 |
Overview: As health systems face increasing pressure to improve outcomes and optimize total cost of care, the clinical laboratory is emerging as a strategic leader in high-value clinical decision-making. This session explores how host response testing in acute infection and suspected sepsis assessments reflects the laboratory’s evolving role as a catalyst for collaboration between laboratorians and clinicians. We will examine how laboratories extend impact beyond diagnostics to deliver measurable value through real world evidence from the clinical implementation of the MeMed BV host response test. Speakers will share experiences illustrating how laboratories have integrated MeMed BV into routine workflows and supported consistent adoption. Through a combination of scientific context and case examples, attendees will gain a clearer understanding of how host response diagnostics can be operationalized at scale and how laboratories can contribute meaningful, data-driven decision support and improve antimicrobial stewardship in acute and emergency care environments.
Objectives:
Presented by: Moderator: Melissa Naiman, PhD - Sr. Director Medical & Scientific Affairs, Beckman Coulter
Speaker Name(s): Octavia M. Peck Palmer, PhD - Division Director, Clinical Chemistry, Vice Chair of Health Equity, Diversity & Inclusion, Associate Professor of Pathology
Ike Northern MT (ASCP), SM, Director of Infectious Disease Testing and Immunology,
CompuNet Clinical Lab
Suzane Silbert, PhD- Director, Esoteric Testing, Microbiology and Research Laboratories, Assistant Professor, Division of Infectious Disease, USF Health Morsani College of Medicine, Tampa General Hospital
Ike Northern,
MS, Director of Infectious Disease Testing,
CompuNet Clinical Laboratories
Ike Northern is the Director of Infectious Disease Testing and Immunology at CompuNet Clinical Lab. He was also appointed Microbiology System Specialist for Premier Health in 2015. In his role at CompuNet, he oversees the Microbiology, Serology, and Molecular departments. Within Premier Health, he is responsible for standardization and consolidation of Microbiology testing across the system.
|
Date: Wednesday July 29 |
 |
Overview: This educational workshop will highlight how the updated CLSI C46 guideline for blood gas and pH analysis impacts current and future clinical practice, with a particular emphasis on preanalytical considerations. The session will begin with Professor John Toffaletti, chair of the CLSI document development committee, providing an overview of key updates, highlighting aspects that are relevant to specimen collection, handling, and mitigation of preanalytical errors. The guideline insights will be complemented by results from a recent U.S. practice survey exploring real-world blood gas testing workflows and challenges, contextualized against CLSI recommendations. The program will conclude with an expert panel discussion addressing how guideline-informed practices can support future quality improvement and consistency in blood gas analysis across care settings.
Objectives:
Presented by: Moderator Anne Skurup, MSc, Principal Medical Advisor, Radiometer Medical ApS
Speaker Name: Dr. John Toffaletti, PhD, Panelists: Dr. Lorin Bachmann, PhD, DABCC, Dr. Xander M. R. van Wijk, PhD, DABCC
John Toffaletti
After completing clinical chemistry training programs at UNC and Hartford Hospital, John Toffaletti has worked in the Clinical Laboratories at Duke University Medical Center since 1979, where he is now Professor of Pathology, Director of the Blood Gas Laboratory, the Clinical Pediatric Laboratory, and several Outpatient Laboratories. He is also the Chief of Clinical Chemistry at the Durham VA Medical Center.
He has written or presented numerous workshops, books, chapters, and seminars on the interpretation of blood gas, cooximetry, ionized calcium, magnesium, lactate (sepsis), kidney function tests (creatinine, cystatin C, GFR), and viscoelastic testing (ROTEM and TEG). He has recently chaired the CLSI document development committed updating the 3rd edition of C46 on Blood Gas and Critical Care Testing. Dr Toffaletti’s research interests include sample collection, pre-analytical errors, analysis, and clinical use of these tests.
Lorin Bachmann
Lorin Bachmann, Ph.D., DABCC, Virginia Commonwealth University, Richmond, VA.
Dr. Bachmann is Professor of Pathology, Co-Director of Clinical Chemistry and Director of the Blood Gas Laboratory at the Virginia Commonwealth University (VCU) Health System. She is a member of the Document Development Committee for the Clinical and Laboratory Standards Institute (CLSI) document C46, Blood Gas, pH, Cooximetry, and Related Measurements – Third Edition. Dr. Bachmann currently serves as a member of the CLSI Board of Directors and as an advisor for the CLSI Chemistry and Toxicology Expert Panel. She is also a member the College of American Pathologists (CAP) Standards Committee. Dr. Bachmann’s clinical and research interests include development of laboratory practice guidelines, standardization of clinical laboratory assays and quality assurance.
Xander van Wijk
Dr. Xander M. R. van Wijk is an Associate Professor in Laboratory Medicine at the University of California San Francisco, where he oversees Clinical Chemistry and Sendout testing. He is also the Principal Consultant at van Wijk Consulting LLC.
Dr. van Wijk extensive background includes roles such as Senior Medical Director at Beckman Coulter Diagnostics, where he contributed to medical strategy and innovation, and Assistant Professor at the University of Chicago, where he oversaw multiple laboratory specialties. His research and experience have established him as a respected authority in the field, with over 60 peer-reviewed articles, book chapters, and several prestigious awards. His research interests are core laboratory diagnostics including laboratory developed tests, cardiac biomarkers, toxicology, pharmacogenomics, and blood gas analysis.
Date: Tuesday, July 28, 10am
Add to Calendar
Overview/Abstract:
This session provides an executive-level overview of how Danaher’s portfolio translates scientific innovation into clinical impact. It will begin with Danaher’s innovation model and then highlight portfolio examples across three disease leadership areas: neurodegenerative disease, oncology, and infectious disease/acute care.
Using the theme “Every Result, Every Life: The Danaher Portfolio at Work,” the talk will show how Danaher Operating Companies combine enabling technologies, scientific expertise, biomarkers, automation, data, workflow integration, and evidence generation to support earlier detection, better disease characterization, and more informed clinical decisions.
Speaker:
Dr. Maximilian Schmid, VP and Chief Medical Officer
Dr. Maximilian Schmid is Vice President and Chief Medical Officer for Danaher Diagnostics, where he leads global medical strategy and Medical & Scientific Affairs across multiple operating companies. He works to align evidence generation, clinical strategy, and field execution to turn innovation into clinical adoption and meaningful patient impact.
A physician-executive with more than 20 years of experience in diagnostics and life sciences, Dr. Schmid has built his career at the intersection of science, medicine, and business transformation. As Global Head of Medical Affairs at Roche Diagnostics, he played a key role in advancing next-generation sequencing (NGS) and expanding non-invasive prenatal testing (NIPT) into routine clinical care. As Chief Commercial Officer at CENTOGENE, he led the strategic repositioning and growth of its global diagnostics business, particularly in rare and neurodegenerative diseases.
Earlier in his career, he was a Senior Associate at McKinsey & Company, advising pharmaceutical and biotech organizations on growth strategy and operations. He is board-certified in Obstetrics and Gynecology with subspecialty training in Maternal-Fetal Medicine and Clinical Genetics, and previously served as a tenured Associate Professor at the Medical University of Vienna, where he led research in prenatal diagnostics and authored more than 35 peer-reviewed publications.
Date: Tuesday, July 28, 11am
Add to Calendar
Overview/Abstract:
Date: Tuesday, July 28, 12pm
Add to Calendar
Overview/Abstract:
This talk will review maternal syphilis diagnostic pathways from a laboratory perspective, including automated treponemal immunoassays, reverse and traditional algorithms, and integrated pregnancy testing. We will illustrate how optimized workflows, high‑sensitivity assays, timely treatment, and stronger coordination across prenatal and ED settings can reduce missed infections and better support patient care, while aligning with updated state mandates.
Speaker:
Sarah Bissonnette, PhD Laboratory Director at Marshfield Clinic Health System
Dr. Sarah W. Bissonnette is a board-certified clinical chemist at Marshfield Clinic Health System-Sanford Health in Marshfield, WI, where she serves as a Laboratory Director, Section Head, Program Director, and Consultant. Dr. Bissonnette also serves as a faculty member in the MLS training program at Marshfield Medical Center. She completed her PhD in Pathology, Microbiology and Immunology as well as her Clinical Chemistry fellowship at Vanderbilt University Medical Center. Dr. Bissonnette is a Diplomate of the American Board of Clinical Chemistry and an active member of the Association for Diagnostics and Laboratory Medicine and the Academy of Clinical Laboratory Physicians and Scientists. As a lab director at Marshfield Clinic Health System, Dr. Bissonnette plays an instrumental role in advancing laboratory medicine. Her work is driven by a commitment to clinical diagnostic innovation and interdisciplinary collaboration, with a deep passion for improving patient care.
Stephanie Mitchell, PhD, D(ABMM) Senior Director Scientific Affairs, Beckman Coulter Diagnostics
Dr. Stephanie Mitchell is Senior Director of Infectious Disease and Microbiology, Medical and Scientific Affairs at Beckman Coulter Microbiology. She is a board-certified clinical microbiologist (ABMM) and trained at Tufts University (Ph.D.) and the University of Pennsylvania (CPEP). Prior to joining Beckman Coulter, she served in Medical and Scientific Affairs at Cepheid and previously served as Medical Director of clinical microbiology laboratories at a large academic healthcare institution. She is currently Adjunct Assistant Professor at School of Medicine at University of Pittsburgh and is active in ASM and CLSI committees.
Date: Tuesday, July 28, 1pm
Add to Calendar
Overview/Abstract:
Discover how NT‑proBNP testing is advancing heart failure evaluation in ED patients with complex co‑morbidities.
In this session, Dr. Allen presents peer‑reviewed evidence evaluating assay performance in routine ED workflows, including diagnostic performance and concordance with established methods. He will highlight interpretation considerations in challenging populations and discuss how analytical performance underpins reliable results, supporting confident, timely clinical decision‑making.
Speaker:
Professor, Medical Director CDU, UFH Chest Pain Ctr, Program Director, University of Florida Health Emergency Medicine
Brandon R. Allen, MD, FACEP, is a Professor of Emergency Medicine and Cardiology at the University of Florida and Medical Director of the UF Health Chest Pain Center and Clinical Decision Unit. A nationally recognized clinical trialist in cardiac biomarkers, he is principal investigator on multicenter NT‑proBNP and high‑sensitivity troponin studies including PRECISE‑HF and is lead author of recent NT‑proBNP publications in Clinical Chemistry and Clinica Chimica Acta.
Date: Tuesday, July 28, 2pm
Add to Calendar
Overview/Abstract:
Experience the practical side of innovation with a real-world case study on implementing MeMed BV, highlighting how laboratory leadership can drive measurable improvements in acute infection assessments, sepsis evaluation and antimicrobial decision-making.
Speaker:
Ike Northern, MS, Director of Infectious Disease Testing, CompuNet Clinical Laboratories Ike Northern is the Director of Infectious Disease Testing and Immunology at CompuNet Clinical Lab. He was also appointed Microbiology System Specialist for Premier Health in 2015. In his role at CompuNet, he oversees the Microbiology, Serology, and Molecular departments. Within Premier Health, he is responsible for standardization and consolidation of Microbiology testing across the system.
Melissa Naiman, PhD, EMT-B, Senior Director, Medical & Scientific Affairs – Acute Care, Beckman Coulter Diagnostics Melissa Naiman, PhD, EMT-B, has focused her career on advancing diagnostics in infectious disease and acute care. Her work spans evidence generation, regulatory strategy, and clinical integration of host response biomarkers—offering laboratorians practical insight into how MDW and MeMed BV testing can support faster, more informed infection and sepsis decisions.
Date: Tuesday, July 28, 3pm
Add to Calendar
Overview/Abstract:
This session will focus on optimizing respiratory test utilization by aligning diagnostics with clinical need to ensure the right test is used at the right time. By integrating evidence‑based algorithms, decision support, and provider engagement, the program enhances diagnostic accuracy, reduces unnecessary testing, and supports diagnostic stewardship and better patient outcomes.
Speaker:
Linoj Samuel, PhD, D(ABMM), Clinical Microbiologist, Detroit, MI
Linoj Samuel, PhD, D(ABMM) is the Division Head of Clinical Microbiology at Henry Ford Health in Detroit, Michigan, where he leads infectious disease diagnostics across a large, integrated healthcare network. Dr. Samuel earned his PhD in Microbiology and Immunology from the University of Arizona and completed a Clinical Microbiology fellowship at the University of Rochester. He is board certified by the American Board of Medical Microbiology. A nationally recognized leader in clinical microbiology, his work focuses on rapid diagnostic technologies, antimicrobial susceptibility testing, and diagnostic stewardship to improve patient outcomes and healthcare efficiency. He has held multiple leadership roles with the American Society for Microbiology, including chairing key committees in clinical and public health microbiology.
Date: Tuesday, July 28, 4pm
Add to Calendar
Overview/Abstract:
The session emphasizes how digital pathology infrastructure, computational pathology workflows, and operational discipline are essential to creating an AI‑ready laboratory, one where AI supports and augments laboratory professionals. Drawing on real‑world experience, the presentation explores how intentional digitization, interoperability, quality systems, and governance form the basis for scalable, trustworthy AI.
Speaker:
Mark Frushone, Global Director of Commercial Development, Digital Pathology at Leica Biosystems
Mark Frushone is the Global Director of Commercial Development, Digital Pathology at Leica Biosystems, based in Vista, California. With over 25 years of experience in healthcare, he is a recognized leader in advancing global digital pathology strategies and adoption. Since joining Leica Biosystems in 2012 as Market Manager for Emerging Markets, Mark has led initiatives to expand digital pathology capabilities worldwide. Prior to Leica, he served as a Senior Application Specialist for the indirect channel at Aperio Inc. He brings nearly two decades of dedicated experience in laboratory and digital pathology environments. Mark holds a Master’s degree in Education from National University and a Bachelor of Science from Central Connecticut State University.
Date: Wednesday, July 29, 10am
Add to Calendar
Overview/Abstract:
In acute care environments, it is critical to have accurate, reliable information as quickly as possible to facilitate rapid decision making and intervention in patients at risk for significant morbidity and mortality. This session will demonstrate how the rapid availability of whole blood testing results through a portable device such as the ABL90 can improve clinical decision-making and ultimately improve patient care. The focus will be on case studies from the intensive care unit, the operating room, and the emergency department to demonstrate the impact of rapidly available testing results.
Speaker:
Bill Clarke, PhD, MBA, DABCC, Professor of Pathology, Johns Hopkins University
Dr. Clarke received his Ph.D. in Analytical Chemistry from the University of Nebraska in Lincoln in 2000, followed by a post-doctoral fellowship in Clinical Chemistry at the Johns Hopkins School of Medicine, ending in 2002. In addition, he received an MBA focused on medical services management from the Carey School of Business at Johns Hopkins in 2007. Following his post-doctoral fellowship, he remained at Johns Hopkins where he is a Professor in the Department of Pathology, the Vice Chair of Pathology for Quality and Regulatory Affairs, and Director of Clinical Chemistry for the hospital. His research interests include clinical mass spectrometry, clinical toxicology, point-of-care testing, and development/validation of biomarkers for use in drug management. Dr. Clarke has published over 210 peer-reviewed manuscripts or book chapters, is a Co-Editor of the textbook Contemporary Practice in Clinical Chemistry, and is Editor-in-Chief of Clinica Chimica Acta.
Date: Wednesday, July 29, 11am
Add to Calendar
Overview/Abstract:
This session will highlight current testing methods for gastroenteritis and how multiplex molecular diagnostics enable fast, comprehensive pathogen detection to improve diagnostic accuracy and support timely, targeted clinical decision-making. It will also review content and results from the context of utilization of GI panel testing within a commercial reference laboratory.
Speaker:
Gerald Capraro, PhD, D(ABMM), Technical Director, Routine and Esoteric Microbiology, Labcorp
Gerald Capraro, PhD, D(ABMM) is a clinical microbiologist and laboratory leader currently serving at Labcorp, where he holds a senior role as the Technical Director, Routine and Esoteric Microbiology services. Dr. Capraro earned his PhD in Microbiology and Immunology from Wake Forest University, following an MS in Molecular Biology/Biotechnology from East Carolina University and a BA in Biology from Catawba College. He completed his postdoctoral fellowship in Medical Microbiology at the University of Nebraska Medical Center. With extensive experience across academic, hospital, and industry settings, Dr. Capraro has led clinical microbiology laboratories and medical affairs programs, previously serving in leadership roles at Carolinas Pathology Group, bioMerieux, and LSU Health Sciences Center. His work centers on infectious diseases, with research and professional interests including antimicrobial resistance, microbial virulence, and the development of advanced molecular diagnostic assays.
Date: Wednesday, July 29, 12pm
Add to Calendar
Overview/Abstract:
This talk serves to highlight the latest advances in blood-based biomarkers for neurodegenerative disease research and clinical care. Dementia is a growing global burden, with Alzheimer’s disease driving 60–70% of cases. More than half involve mixed pathology, making early, accurate diagnosis a critical challenge. Blood-based biomarkers are expanding the tools for Alzheimer’s research today and enabling patient stratification for tomorrow’s clinical care. Assessment is moving beyond CSF and PET toward plasma biomarkers spanning the amyloid, tau, inflammation, and neurodegeneration framework.
Speaker:
Charbel Abou Diwan, PhD, Sr Director Medical & Scientific Affairs
Neurological Disease, Beckman Coulter Diagnostics
Dr. Charbel Abou-Diwan is Senior Director of Medical and Scientific Affairs for Neurological Diseases, with over 15 years of experience in diagnostics, clinical laboratories, and medical strategy. His current work focuses on advancing the adoption of innovative biomarkers in Alzheimer’s disease, including blood-based diagnostics and care pathway optimization. He is actively engaged in global laboratory medicine leadership through ADLM and IFCC, where he has held multiple leadership roles.
Date: Wednesday, July 29, 1pm
Add to Calendar
Overview/Abstract:
This talk review the diverse epidemiology of antimicrobial resistance in Gram-negative and Gram-positive organisms, review antimicrobial susceptibility testing (AST) methods, breakpoint interpretations and updates and the advantages of accurate AST for the detection of AMR and MDROs for right first-time results to drive appropriate antibiotic therapy and antimicrobial stewardship initiatives.
Speaker:
Stephanie Mitchell, PhD, D(ABMM), Principal Scientist, Senior Director Scientific Affairs, Beckman Coulter Diagnostics
Dr. Stephanie Mitchell is Senior Director of Infectious Disease and Microbiology, Medical and Scientific Affairs at Beckman Coulter Microbiology. She is a board-certified clinical microbiologist (ABMM) and trained at Tufts University (Ph.D.) and the University of Pennsylvania (CPEP). Prior to joining Beckman Coulter, she served in Medical and Scientific Affairs at Cepheid and previously served as Medical Director of clinical microbiology laboratories at a large academic healthcare institution. She is currently Adjunct Assistant Professor at School of Medicine at University of Pittsburgh and is active in ASM and CLSI committees.
Date: Wednesday, July 29, 2pm
Add to Calendar
Overview/Abstract:
This presentation examines how advances in the analytical sensitivity of the DxI 9000 Immunoassay Analyzer translate into tangible clinical value at the point of care. We will review the assay design improvements that allow established biomarkers to be measured earlier and reported with greater confidence. We then explore emerging clinical use cases, from high-sensitivity cardiac troponin for earlier rule-out of myocardial infarction to improved detection across endocrine and oncology testing. Provides insights for earlier intervention and faster, more confident decisions.
Speaker:
Chris Bird, DPhil, Chief Medical Officer, Beckman Coulter Diagnostics
Dr. Chris Bird oversees advancing medical excellence and delivering meaningful medical impact across key disease areas through integrated evidence generation and medical education. Chris joined Beckman Coulter in 2025, bringing more than 25 years of leadership experience spanning diagnostics, molecular medicine, and cell therapy. His background includes serving as Chief Medical Officer at BioPorto, leading Medical & Scientific Affairs at Roche Diagnostics, North America, and co-founding and leading the cell therapy company, Chimeris. Chris holds a Bachelor of Science in Physiology from Brigham Young University, a Master of Science in Biochemistry and Molecular Biology from University of California, Los Angeles, and a Doctor of Philosophy in Molecular Immunology from the University of Oxford as an Abraham Scholar. In addition, he has graduate business degrees from London Business School and ESADE.
Date: Wednesday, July 29, 3pm
Add to Calendar
Overview/Abstract:
This presentation outlines how Cytiva helps diagnostic developers simplify complex assay development through integrated solutions such as magnetic beads, lyophilization, and membrane technologies. It emphasizes accelerating time to market, reducing risk, and enabling scalable manufacturing through customizable services and strong quality systems. Cytiva’s approach combines workflow simplification, regulatory readiness, and supply security to support innovation in molecular and point-of-care diagnostics. By addressing industry challenges like stability, cost, and regulatory complexity, Cytiva positions itself as a strategic partner that enables faster, reliable, and scalable diagnostic solutions.
Speaker:
Donald Green, Diagnostics Business Development Manager
Donald is a thoughtful and results-driven business development manager with over 15 years of experience in the diagnostics industry, including 6+ years at Cytiva, bringing strong expertise in diagnostics and assay development.
He’s naturally curious and analytical, with a talent for turning complex data into clear, practical insights and helping translate ideas into real-world solutions. He builds strong, trusted relationships through a collaborative and grounded approach, and is known for staying focused on outcomes that drive real impact. He values clear, honest communication and consistently works to keep teams aligned, moving forward, and focused on what matters most.
Date: Wednesday, July 29, 4pm
Add to Calendar
Overview/Abstract:
Discover how SCIEX—proudly part of the Danaher family of operating companies—is advancing clinical mass spectrometry from early research through routine diagnostics. As a leader in LC-MS/MS technology, SCIEX is dedicated to empowering laboratories with solutions that deliver high-quality, actionable insights to support clinical decision-making. This presentation will highlight the latest updates to SCIEX’s in vitro diagnostic (IVD) portfolio, with a focus on enhancing workflow efficiency, confidence, and compliance in clinical laboratories. Attendees will learn about the new integration of SCIEX OS software within our IVD solutions, including powerful features such as automated flagging and customizable decision rules designed to streamline data review and support consistent interpretation of results. Additionally, we will introduce our IVD liquid chromatography (LC) offering—completing the LC-MS/MS workflow with a fully compatible Class I Medical Device solution. Together, these innovations represent SCIEX’s commitment to delivering robust, scalable technologies that help laboratories translate complex data into meaningful clinical impact.
Speaker:
Michael Jarvis, Senior Product Manager, SCIEX
Michael joined SCIEX in 2008, and has spent the majority of his career developing and championing the use of mass spectrometry in the clinical laboratory. Michael has held a variety of roles of increasing responsibility within the organization including Global Clinical Technical Marketing Manager, Global Market Manager for Clinical Diagnostics, Senior Ideation Manager, and most recently Senior Product Manager Clinical, Michael was integral to the launches of the Citrine MS/MS system, the Jasper HPLC system, and the SCIEX OS software for IVD systems.
| Abstract Titles | Poster # | Featured Date | |
|---|---|---|---|
 |
Survey of Preanalytical Errors in Blood Gas Sample Collection and Analysis: Frequency, Impact, and Improvement Priorities Across U.S. Healthcare Settings | A-356 | Tuesday |
| Blood Gas Sample Storage Time Recommendations and Age Tracking Practices: A Survey of Current Practices Across U.S. Health Care Settings (Won ADLM’s POCT Division Abstract Award!) | A-355 | Tuesday | |
 |
Trends in Invasive Group A Streptococcus (GAS) Testing Across U.S. Care Settings assessed using a nationally representative EHR platform (2023–2025) | A-385 | Tuesday |
| Prevalence of Co-Detection with E. coli subtypes in Multiplex Gastrointestinal Panels | A-305 | Tuesday | |
 |
Clinical value of host-response testing and 4-plex viral PCR in adults presenting to the Emergency Department | A-088 | Tuesday |
| Multicenter evaluation of the new Access HBsAg assay with highly sensitive HBsAg detection on the DxI 9000 Access Immunoassay Analyzer | B-164 | Wednesday | |
| Clinical Evaluation of the Newly Approved Access HBsAg assay for Enhanced Detection, Workflow Efficiency, and Analytical Integrity | B-163 | Wednesday | |
| Evaluation of a newly developed Access anti-HAV IgM immunoassay on the DxI 9000 Immunoassay Analyzer | B-165 | Wednesday |
Through expertise and strategic partnerships, we are pushing boundaries with next-generation technologies that improve workflow and drive confidence in patient results. From innovative biomarkers to workflow automation, here are just a few of the solutions that will be on display at ADLM.
Advantaged Workflows
Accelerate more precise clinical decision-making—from sample collection to diagnostic insight—unlocking the power of every sample and improving workflow to create new value for your laboratory teams.
Learn more
Digital Hematology
Discover how we’re delivering more insights from the CBC so you can support a higher standard of care with a growing menu of advanced biomarkers and unparalleled clinical sensitivity.
Learn more
High-Sensitivity Diagnostics
Revolutionize your core lab’s impact with unprecedented high-sensitivity diagnostic testing across diverse areas like cardiovascular disease, infectious disease, and women’s health.
Learn more
Catch up with these educational resources shared at ADLM 2025.
Tell us you're coming and we'll connect you with a member of the Beckman Coulter team
for a tailored demo of the solutions that matter to you.
Complete the form below and we’ll reach out soon.
Thank you for your request.
A Beckman Coulter representative will contact you shortly.
English
